Forced expiratory flows and diffusion capacity in infants born from mothers with pre-eclampsia

Clement L. Ren MD, MBA1,2 | James E. Slaven MS3 | David M. Haas MD4 | Laura S. Haneline MD5 | Christina Tiller RRT6 | Graham Hogg BS4 | Jeffrey Bjerregaard RRT6 | Robert S. Tepper MD, PhD6

1Division of Pulmonary and Sleep Medicine, Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania, USA
2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
3Department of Biostatistics and Health Data Science, Indiana University School of Medicine, Indianapolis, Indiana, USA
4Department of Obstetrics and Gynecology, Indiana University School of Medicine, Indianapolis, Indiana, USA
5Department of Pediatrics, Division of Neonatal-Perinatal Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA
6Department of Pediatrics, Division of Pulmonary, Allergy, and Sleep Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA

Correspondence
Robert S. Tepper, MD, PhD, Department of Pediatrics, Indiana University School of Medicine, Indiana University School of Medicine, Riley Hospital for Children, 705 Riley Hospital Dr, Indianapolis, IN 46202, USA.
Email: rtepper@iu.edu

Funding information
National Heart, Lung, and Blood Institute, Grant/Award Number: R01HL122215

Abstract
Rationale: Animal models suggest pre-eclampsia (Pre-E) affects alveolar development, but data from humans are lacking.

Objective: Assess the impact of Pre-E on airway function, diffusion capacity, and respiratory morbidity in preterm and term infants born from mothers with Pre-E.

Methods: Infants born from mothers with and without Pre-E were recruited for this study; term and preterm infants were included in both cohorts. Respiratory morbidity in the first 12 months of life was assessed through monthly phone surveys. Raised volume rapid thoracoabdominal compression and measurement of diffusion capacity of the lung to carbon monoxide (DLCO) were performed at 6 months corrected age.

Measurements and Main Results: There were 146 infants in the Pre-E cohort and 143 in the control cohort. The Pre-E cohort was further divided into nonsevere (N = 41) and severe (N = 105) groups. There was no significant difference in DLCO and DLCO/alveolar volume among the three groups. Forced vital capacity was similar among the three groups, but the nonsevere Pre-E group had significantly higher forced expiratory flows than the other two groups. After adjusting for multiple covariates including prematurity, the severe Pre-E group had a lower risk for wheezing in the first year of life compared to the other two groups.

Conclusions: Pre-E is not associated with reduced DLCO, lower forced expiratory flows, or increased wheezing in the first year of life. These results differ from animal models and highlight the complex relationships between Pre-E and lung function and respiratory morbidity in human infants.

Keywords
prematurity, wheezing
1 | INTRODUCTION

Pre-eclampsia (Pre-E) is a serious complication of pregnancy that occurs in approximately 5% of pregnancies in the USA. Pre-E is characterized by maternal hypertension and systemic vascular endothelial dysfunction. Although the pathogenesis of Pre-E is not well-defined, several studies have demonstrated that women with Pre-E have increased circulating levels of antiangiogenic factors such as soluble FMS-like Tyrosine Kinase-1 (sFlt-1). Infants born from mothers with Pre-E have a reduced risk for retinopathy of prematurity, a condition caused by excess retinal angiogenesis and neovascularization. In addition, infants born from hypertensive women have reduced skin capillary density. These observations suggest that the antiangiogenic milieu of pregnant women with Pre-E affects vascular development in the fetus. Recent evidence from a murine model of the early onset immune mediated subtype of Pre-E suggests that the placenta plays a key role in mediating the effects of Pre-E on fetal lung development.

Disruption of pulmonary vascular development is linked to impaired alveolar growth, a hallmark feature of bronchopulmonary dysplasia (BPD). Increased cord blood sFlt-1 is also associated with an enhanced risk of BPD in preterm infants. A rat model of Pre-E utilizing intra-amniotic injection of sFlt-1 demonstrated decreased alveolar number and reduced pulmonary vessel density at 14 days of age, which corresponds to 1 year of human life. Furthermore, a history of maternal Pre-E is associated with increased rates of asthma, allergy, and eczema. Taken together, these clinical and animal data suggest that the effect of Pre-E on angiogenesis may affect respiratory function in infants with Pre-E. However, there are limited data on airway function and, to our knowledge, no data on the gas transfer in infants with a history of maternal Pre-E.

The objective of our study was to assess the impact of Pre-E on respiratory outcomes in early infancy, which included lung function and respiratory morbidity. We hypothesized that the in utero antiangiogenic environment of pre-E would result in impaired lung growth and development with decreased parenchymal and airway function, as well as increased respiratory morbidity in infants born of pregnant women with Pre-E. To test this hypothesis, we recruited a cohort of pregnant women with Pre-E and a cohort of normotensive pregnant women with similar gestational ages (GA) that included preterm and term infants. We evaluated parenchymal function with measurements of diffusion capacity of the lung and lung volume and airway function with measurements of forced expiratory flows (FEFs). Infant pulmonary function tests (IPFTs) were performed at approximately 6 months corrected age, and their respiratory status was followed through 12 months corrected age.

2 | METHODS

2.1 | Study population and design

This was a single-center, prospective, observational cohort study (NCT02639676). Potential study participants were recruited from three local hospitals in Indianapolis, IN, USA. Inclusion criteria for the study cohort included a clinical diagnosis of Pre-E (using definitions contained in the American College of Obstetrics and Gynecology criteria for Pre-E) and diffusion capacity of the lung to carbon monoxide (DLCO) were performed. In addition, FEFs using the raised volume rapid thoracoabdominal compression technique were measured and quantified by forced vital capacity (FVC), FEFs between 25% and 75% expired FVC (FEF25-75), FEF at 50% and 75% expired FVC (FEF50, FEF75), as well as forced expired volume in 0.5 s (FEV0.5). Data quality was determined using published guidelines and only research quality data were used for analysis.

2.3 | Statistical analysis

The Pre-E cohort was evaluated as a single group, as well as divided into two groups, nonsevere Pre-E and severe Pre-E, using the American College of Obstetrics and Gynecology criteria for Pre-E with severe features. Clinical and demographic comparisons were performed using χ² tests for categorical variables and Student’s t-tests and Wilcoxon rank-sum tests for continuous variables, depending on the data.
3 | RESULTS

A total of 430 infants were screened, and 289 were enrolled, 146 in the Pre-E group and 143 in the normotensive comparison cohort. Figure 1 illustrates the derivation of the study cohort. From the 85 infants who had PFTs, we were able to obtain research quality DLCO data from all of them and research quality raised volume rapid thoracoabdominal compression (RVRTC) data in 67 (79%). The research quality rate of RVRTC data is similar to that of other studies.19-22 The demographic and clinical features of the control and Pre-E (nonsevere and severe) cohorts are summarized in Table 1. There were no differences among groups for sex and maternal race; however, as expected, GA, birth weight, and birth length of the severe Pre-E infants were significantly lower compared to infants in the control and nonsevere Pre-E groups. Severe Pre-E infants were also more likely to have FGR, to be small of GA, and to be born to women treated with ANS. No significant differences were observed among the groups in terms of the need for mechanical ventilation, surfactant therapy, development of BPD, history of maternal smoking, and second-hand smoke exposure. A similar pattern of clinical features was seen when comparisons were restricted to the infants who had IPFT obtained (data not shown).

IPFTs were performed at a mean corrected age of 7.99 months (SD 2.69, range = 4.14–19.53), and the results are summarized in Table 2. DLCO, DLCO/VA, and VA were not different for the control and Pre-E group, even when the latter was divided into the nonsevere and severe Pre-E groups. In addition, hemoglobin concentration did not differ among the three groups (11.5 ± 1.2, 11.3 ± 1.4, and 11.7 ± 1.2; \( p > 0.3728 \)).

Although there were no statistically significant differences in IPFT results in the total Pre-E cohort compared to the controls, when Pre-E was divided by severity, the nonsevere Pre-E cohort had significantly higher FEFs compared to the controls and severe Pre-E infants (Table 2). In addition, \( FEV_{0.5} \) was higher in the nonsevere Pre-E group, although the difference did not reach statistical significance (\( p = 0.058 \)).

There were 234 infants (control, \( N = 108 \); Pre-E, \( N = 126 \)) whose caregivers responded to at least one survey in the first 6 months of life, and again after 6 months of life. The demographics and clinical features of this group were similar to those of the entire cohort and the proportion of respondents was similar in both the control group and pre-E groups. Among all infants with respiratory questionnaires, 98 (42%) had at least one episode of wheezing reported in the first year of life. There was no significant difference in the proportion of subjects with No Wheeze among the three groups (control, nonsevere Pre-E, and severe Pre-E). Preterm birth, lower birth weight, lower birth length, and lower GA, maternal smoking, and history of asthma were also associated with a higher prevalence of wheezing. An analysis restricted to only those infants who also had IPFT revealed a similar pattern. Using covariates related to the risk of wheeze selected from the bivariate analysis (Table 3) and additional variables based on clinical relevance (listed in Section 2), we then performed multivariable logistic regression modeling for the outcome of Wheeze versus No Wheeze. The odds ratio (OR) of Wheeze was significantly lower in the combined Pre-E group compared to controls (0.47; \( p < 0.009 \)). When the Pre-E group was divided into nonsevere and severe Pre-E, each of the Pre-E groups had OR for Wheeze of less than 1.0; however, compared to the control group, only the severe Pre-E group, which composed the majority of Pre-E subjects, had significantly lower risk for wheeze (Table 4). Family history of asthma, maternal smoking, and ANS were all included in the logistic model based upon their associated increased risk of Wheeze in the bivariate analysis (Table 3), only ANS, which were more frequent in the severe Pre-E group, was statistically significant, while family history of asthma and maternal smoking were still associated with an increased risk of wheeze with \( p \)-values <0.10 (Table 1). Very few infants were hospitalized for respiratory illness following discharge, precluding a detailed analysis of this respiratory outcome.

4 | DISCUSSION

In this single-center prospective cohort study of infants born from mothers with Pre-E, no differences were detected in the lung parenchymal function of gas exchange and lung volume, as assessed by DLCO, DLCO/VA, or VA, when compared to control infants born from normotensive mothers. This finding does not support our hypothesis nor agree with animal models of Pre-E, which suggest impaired alveolar development in the offspring of mothers with Pre-E. However, we did find that airway function, assessed by FEFs, was actually higher in the nonsevere Pre-E group compared to control and severe Pre-E groups. Although the nonsevere Pre-E group had higher FEFs, the severe Pre-E group, which did not have higher FEFs, had a lower risk for wheeze in the first year of life when adjusted for
covariates including GA. These findings highlight the complex relationships among prematurity, lung function, and respiratory morbidity in human infants born from mothers with Pre-E.

We are not aware of other studies that have assessed DLCO as a respiratory outcome in offspring of mothers with Pre-E. The majority of infants born following maternal Pre-E are preterm because labor is either induced or a caesarean section is performed at a premature GA to protect the mother from severe Pre-E. Therefore, preterm birth, which is associated with impaired alveolar development and increased respiratory morbidity, becomes an important confounder in the assessment of respiratory outcomes of lung function and respiratory morbidity. We, therefore, used a control group from normotensive pregnancies that included preterm and term births. Our findings that DLCO and VA did not differ between Pre-E (nonsevere and severe) and normotensive control group suggests that Pre-E did not significantly impair alveolar development when evaluated at a mean corrected-age of 7–8 months.

Our findings related to parenchymal function do not support our initial hypothesis and are not consistent with current animal models of Pre-E. Tang et al. reported that the amniotic administration of the anti-angiogenic factor FLT-1 to pregnant rats 2 days before delivering pups via caesarian section resulted in decreased alveolar number, reduced pulmonary vessel density, and right ventricular hypertrophy. More recently, Taglauer et al. used a heme oxygenase-1
null mouse model of Pre-E to demonstrate disrupted alveolar formation and altered airway development. This model was also associated with a downregulation of angiogenic and epithelial pathways, as well as an upregulation of inflammatory and extracellular matrix pathways, suggesting multiple molecular pathways contributing to the observed pulmonary phenotype. It is possible that the Pre-E infants we evaluated may have demonstrated impaired alveolar development if evaluated during the neonatal period and subsequently exhibited catch-up in alveolar development before our evaluation. However, the animal models of Pre-E that demonstrated impaired alveolar development often evaluated animal offspring at human developmental age equivalent to our study in human infants. In addition, there are currently no longitudinal data in humans to indicate that there is catch-up lung growth following preterm birth or maternal pre-E. Therefore, it remains unclear how well the current animal models of Pre-E reflect clinical Pre-E, and the various subtypes, which may result from multiple different factors and be associated with multiple comorbidities, such as FGR and prematurity, which can affect lung development.

In contrast to no differences in DLCO and VA, we did find higher FEFs in infants of mothers with nonsevere Pre-E. This finding is consistent with the higher FEFs reported in older children born of mothers with Pre-E, although that study of older children was restricted to subjects born preterm with GA < 28 weeks or weighing <1000 g. In both that study and ours, FVC did not differ between Pre-E and control groups, suggesting that the higher FEFs were

| TABLE 1 Clinical features of the cohort |
|----------------------------------------|
|                                         |
| N                                      | Control | Nonsevere Pre-E | Severe Pre-E | p Value |
|----------------------------------------|---------|-----------------|--------------|---------|
| Sex                                    |         |                 |              |         |
| Female                                 | 61 (43.0) | 19 (46.3)   | 56 (53.3)    | 0.2695  |
| Male                                   | 81 (57.0) | 22 (53.7)   | 49 (46.7)    |         |
| Maternal race                          |         |                 |              | 0.6416  |
| Black                                  | 67 (47.2) | 17 (41.5)   | 57 (54.3)    |         |
| White                                  | 67 (47.2) | 20 (48.8)   | 43 (41.0)    |         |
| Multi                                  | 7 (4.9)  | 4 (9.8)       | 4 (3.8)      |         |
| Unknown                                | 1 (0.7)  | 0 (0)         | 1 (1.0)      |         |
| Preterm delivery                       | 55 (38.7) | 8 (19.5)   | 66 (62.9)    | <0.0001bc|
| Gestational age                        |         |                 |              | <0.0001bc|
| Mean (SD)                              | 37.11 (3.55) | 37.66 (2.46) | 35.32 (3.49) |         |
| Median (95% CI)                        | 38.4 (35.1, 39.9) | 37.6 (37.0, 39.3) | 36.3 (33.6, 37.3) |         |
| Birth weight (kg)                      |         |                 |              | <0.0001bc|
| Mean (SD)                              | 2.98 (2.52, 3.36) | 2.9978 (0.8205) | 2.3184 (0.7744) |         |
| Median (95% CI)                        | 2.98 (2.52, 3.36) | 3.19 (2.66, 3.51) | 2.41 (1.78, 2.89) |         |
| Birth length (cm)                      |         |                 |              | <0.0001ab|
| Mean (SD)                              | 47.87 (5.20) | 48.48 (4.95) | 45.19 (5.07) |         |
| Median (95% CI)                        | 49.0 (46.0, 51.0) | 49.0 (48.3, 52.0) | 47.0 (43.0, 48.5) |         |
| Fetal growth restriction               | 16 (11.4) | 5 (12.2)       | 27 (25.7)    | 0.0081a |
| Family history of asthma               | 31 (21.8) | 11 (26.8)     | 28 (26.7)    | 0.6273  |
| Size for GA                            |         |                 |              |         |
| Small for GA                           | 14 (9.9) | 5 (12.2)       | 26 (24.8)    | 0.0014ab|
| Appropriate for GA                     | 119 (84.4) | 32 (78.1) | 79 (75.2)    |         |
| Large for GA                           | 8 (5.7) | 4 (9.8)        | 0 (0)        |         |
| Antenatal steroids                     | 55 (39.0) | 12 (29.3)     | 63 (60.0)    | 0.0004ab|

Note: Values in parentheses represent percentages except as noted. Superscripted letter indicate which pairwise comparison was made (a, control vs. severe Pre-E; b, nonsevere Pre-E vs. severe Pre-E). Abbreviations: CI, confidence interval; GA, gestational age; Pre-E, pre-eclampsia.
## TABLE 2  Infant lung function results

| PFT measure | Control (n = 108) | Nonsevere pre-Eclampsia (n = 34) | Severe pre-Eclampsia (n = 92) | Mean difference (95% CI) (control vs. nonsevere) | Mean difference (95% CI) (control vs. severe) | Mean difference (95% CI) (nonsevere vs. severe) | Omnibus p value |
|-------------|-------------------|----------------------------------|------------------------------|-------------------------------------------------|-----------------------------------------------|---------------------------------------------|----------------|
| DLCO (ml/min/mmHg) | 2.6 (0.1)        | 2.6 (0.1)                        | 2.5 (0.1)                   | -0.0 (-0.3, 0.3)                                | 0.1 (-0.2, 0.3)                              | 0.1 (-0.2, 0.4)                                  | 0.7786 |
| DLCO/VA (ml/min/mmHg/ml) | 6.9 (0.2)       | 7.1 (0.3)                        | 7.1 (0.2)                   | -0.2 (-0.8, 0.4)                                | -0.2 (-0.6, 0.2)                             | -0.0 (-0.6, 0.6)                                 | 0.6103 |
| VA (ml)     | 410.6 (12.6)     | 397.8 (19.3)                     | 389.2 (13.0)                | 12.8 (-27.3, 52.8)                              | 21.5 (-7.6, 50.5)                             | 8.7 (-33.4, 50.8)                                | 0.3391 |
| FVC (ml)    | 271.4 (6.5)      | 275.2 (9.8)                      | 265.4 (7.1)                 | -3.8 (-24.3, 16.7)                              | 6.0 (-8.9, 20.9)                              | 9.8 (-12.1, 31.8)                                | 0.6102 |
| V50 (ml/s)  | 444.6 (17.8)     | 537.0 (26.8)                     | 457.9 (19.3)                | -92.4 (-148.6, -36.2)                           | -133 (-54.2, 27.6)                            | 79.1 (18.9, 139.3)                               | 0.0061 |
| FEF25-75 (ml/s) | 412.0 (16.2)    | 495.0 (24.4)*                    | 418.5 (17.6)                | -83.0 (-134.1, -31.9)                           | -6.5 (-43.6, 30.7)                            | 76.5 (21.8, 131.3)                               | 0.0062 |
| V25 (ml/s)  | 252.0 (12.5)     | 289.1 (18.8)                     | 251.0 (13.5)                | -37.1 (-76.4, 2.3)                              | 1.0 (-27.6, 29.6)                             | 38.1 (-4.0, 80.2)                                | 0.1525 |
| FEV0.5 (ml) | 211.7 (5.4)      | 231.2 (8.1)                      | 210.5 (5.8)                 | -19.5 (-36.4, -2.5)                             | 1.2 (-11.2, 13.5)                             | 20.6 (2.5, 38.8)                                 | 0.0578 |

Note: The total numbers for each group are shown in the table. Values are means (standard errors) for each group with 95% CI for the difference between means and p-value from ANCOVA models. * Pairwise comparison between control vs. severe Pre-E.

Abbreviations: ANCOVA, analysis of covariance; CI, confidence interval; DLCO, diffusion capacity of the lung to carbon monoxide; FEF25-75, forced expiratory flow between 25% and 75% of FVC; FEV0.5, forced expiratory volume in 0.5 s; FVC, forced vital capacity; PFT, pulmonary function test; Pre-E, pre-eclampsia; V50, flow at 50% of FVC; V25, flow at 75% of FVC; VA, alveolar volume.
|                  | No Wheezing | Wheezing | p Value |
|------------------|-------------|----------|---------|
| **N**            | 136         | 98       |         |
| **Group**        |             |          |         |
| Control          | 55 (40.4)   | 53 (54.1)| 0.1184  |
| Pre-eclamptic (low severity) | 22 (16.2)   | 12 (12.2)|         |
| Pre-eclamptic (high severity) | 59 (43.4)   | 33 (33.7)|         |
| **Sex**          |             |          |         |
| Female           | 68 (50.0)   | 43 (43.9)| 0.3548  |
| Male             | 68 (50.0)   | 55 (56.1)|         |
| **Race**         |             |          |         |
| White            | 62 (45.6)   | 46 (46.9)| 0.8380  |
| Other            | 74 (54.4)   | 52 (53.1)|         |
| **Term**         |             |          |         |
| Full Term        | 81 (59.6)   | 45 (45.9)| 0.0389  |
| Preterm          | 55 (40.4)   | 53 (54.1)|         |
| **Gestational age** |     36.89 (3.30); 37.29 (35.79, 39.29) | 35.73 (3.84); 36.43 (34.00, 38.86) | 0.0215 |
| **Birth weight (kg)** | 2.7443 (0.7662); 2.79 (2.04, 3.13) | 2.5366 (0.8622); 2.63 (2.04, 3.13) | 0.0732 |
| **Birth length**  | 47.49 (5.39); 48.50 (47.00, 50.50) | 45.89 (5.32); 46.75 (43.50, 49.53) | 0.0064 |
| **Surfactant treatment** | No: 127 (93.4); 9 (6.6) | Yes: 9 (6.6); 9 (9.2) | 0.4674 |
| **Mechanical Ventilation** | No: 127 (93.4); 9 (6.6) | Yes: 9 (6.6); 10 (10.2) | 0.3217 |
| **Bronchopulmonary dysplasia** | No: 133 (97.8); 3 (2.2) | Yes: 93 (94.9); 5 (5.1) | 0.2290 |
| **Fetal growth restriction** | No: 116 (85.3); 20 (14.7) | Yes: 82 (83.7); 16 (16.3) | 0.7346 |
| **Secondhand smoke exposure** | No: 131; 5 (55.7) | Yes: 94 (41.8); 4 (44.4) | 0.8737 |
| **Mother smoked during pregnancy** | No: 111 (81.6); 25 (18.4) | Yes: 69 (70.4); 29 (29.6) | 0.0447 |
| **Family history of asthma** | No: 107 (78.7); 29 (21.3) | Yes: 67 (68.4); 31 (31.6) | 0.0748 |

(Continues)
nonsevere and severe Pre-E, as well as prematurity, differ in their effects on baseline airway development and function, as well as immune development and responses to stimuli. Therefore, the relationship between airway function and wheezing previously observed in full-term infants may be more indirect and may not apply in our populations of infants.

BD responsiveness in term infants is associated with an increased risk of wheezing in infancy,30,31 and in contrast, there is a low BD response rate in preterm infants.22 We did not measure BD response in our study, so we could not assess its contribution to wheezing risk in Pre-E infants. However, it is possible that the higher rate of prematurity in the severe Pre-E cohort was another factor in their lower risk of wheezing.

Our study has several strengths and limitations. One of the strengths of our study was the ability to obtain a detailed assessment of lung function in infants. We were able to address the effect of Pre-E on lung parenchymal development, as well as airway function. Importantly, we evaluated control subjects from normotensive pregnancies with a balanced mix of GA and sex, as these factors can contribute to alterations in lung growth and development. Preterm infants with chronic lung disease of infancy (CLDI) have lower DLCO, but normal VA compared to full-term infants.32 However, the effect of Pre-E upon alveolar development may be less than that observed with CLDI. Our study also had limitations. All of the infants were recruited from a single health system, which could have led to bias in the study population or treatment of Pre-E. Although our cohort size was large for an IPFT study, the number of infants evaluated was still relatively small, potentially rendering us underpowered to detect some associations. Although we accounted for multiple covariates in our analysis, we were unable to adjust for all potential confounders, such as respiratory viral infections. The number of very low GA infants was small, and it is possible that the impact of Pre-E on pulmonary outcomes in extremely low GA neonates would be different from our observations. Lastly, our DLCO measurement was obtained in infants sleeping, which may have limited our ability to detect smaller differences of impaired alveolar development, which may only be present under conditions of increased cardiac output, such as exercise.33

In summary, the results of our study do not support the hypothesis that in utero Pre-E exposure leads to impaired lung parenchymal development in humans. The differences between our findings in humans and those reported from animal models may be due to differences in the impact of antiangiogenic factors on lung development or the ability of the human lung to rapidly compensate for in utero antiangiogenic factors. However, we separately found better airway function and decreased wheeze, but not in the same severity group of Pre-E offspring. Therefore, differing Pre-E severity may represent different molecular pathways, which could result in differing pulmonary phenotypes. Further research is needed to obtain a more comprehensive understanding of the effect of Pre-E on lung development and respiratory morbidity.

### TABLE 3 (Continued)

| Size for gestational age (GA) | No Wheezing | Wheezing | p Value |
|------------------------------|-------------|----------|---------|
| Small for GA                | 22 (16.2)   | 15 (15.3) | 0.8469  |
| Appropriate for GA          | 108 (79.4)  | 80 (81.6) |         |
| Large for GA                | 6 (4.4)     | 3 (3.1)   |         |

Antenatal steroids

| No | Wheezing |
|----|----------|
| No | 85 (62.5) | 41 (41.8) | 0.0018  |
| Yes| 51 (37.5) | 57 (58.2) |         |

Note: Values are means (standard deviations); medians (IQRs) for continuous variables and frequencies (row percentages) for categorical variables, with p-values from Wilcoxon and χ² tests, respectively.

Abbreviations: GA, gestational age; IQR, interquartile range.

### TABLE 4 Logistic regression model for reported wheeze

| Group                              | Odds ratio (95% CI) | p Value |
|------------------------------------|---------------------|---------|
| Nonsevere pre-eclampsia vs. control| 0.61 (0.26, 1.41)   | 0.2439  |
| Severe pre-eclamptic vs. control   | 0.42 (0.22, 0.70)   |         |

Sex

| Female | Odds ratio (95% CI) | p Value |
|--------|---------------------|---------|
| Female | 0.81 (0.46, 1.42)   | 0.4683  |
| Male   | Reference           |         |

Gestational age

| Gestational age | Odds ratio (95% CI) | p Value |
|-----------------|---------------------|---------|
| 0.96 (0.86, 1.07)| 0.0439              |         |

Mother smoked during pregnancy

| Mother smoked during pregnancy | Odds ratio (95% CI) | p Value |
|--------------------------------|---------------------|---------|
| 1.88 (0.99, 3.60)             | 0.0556              |         |

Family history of asthma

| Family history of asthma | Odds ratio (95% CI) | p Value |
|--------------------------|---------------------|---------|
| 1.71 (0.91, 3.21)        | 0.0952              |         |

Antenatal steroids

| Antenatal steroids | Odds ratio (95% CI) | p Value |
|--------------------|---------------------|---------|
| 2.23 (1.04, 4.79)  | 0.0387              |         |

Note: Values are reported as odds ratios (95% CI). The model includes independent variables selected from Table 3 with p < 0.10. Comparisons of dichotomous variables are for “yes” compared to “no.”

Abbreviation: CI, confidence interval.
AUTHOR CONTRIBUTIONS
Robert S. Tepper, David M. Haas, and Laura S. Haneline were responsible for study design. Clement L. Ren, Robert S. Tepper, David M. Haas, Laura S. Haneline, and James E. Slaven contributed to data analysis and interpretation. James E. Slaven performed the statistical analysis. Christina Tiller, Graham Hogg, and Jeffrey Bjerggaard contributed to study participant enrollment and tracking and performing study procedures. Clement L. Ren wrote the first draft of the manuscript. Robert S. Tepper, David M. Haas, Laura S. Haneline, Christina Tiller, James E. Slaven, and Clement L. Ren contributed to the final version of the manuscript.

ACKNOWLEDGMENT
This study was funded by NIH R01HL122215 (R. S. T. and L. S. H.).

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Clement L. Ren https://orcid.org/0000-0003-4431-0644
Robert S. Tepper https://orcid.org/0000-0003-3322-5903

REFERENCES
1. Eiland E, Nzerue C, Faulkner M. Preeclampsia 2012. J Pregnancy. 2012;2012:586578.
2. Fox KA, Longo M, Tamayo E, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol. 2011;205(366):e361–e365.
3. Staff AC, Braekke K, Harsem NK, Lyberg T, Holthe MR. Circulating concentrations of sFlt1 (soluble fms-like tyrosine kinase 1) in fetal and maternal serum during pre-eclampsia. Eur J Obstet Gynecol Reprod Biol. 2005;122:33–39.
4. Yu XD, Branch DW, Karumanchi SA, Zhang J. Preeclampsia and retinopathy of prematurity in preterm births. Pediatrics. 2012;130:e101–e107.
5. Antonios TF, Raghuraman RP, D’Souza R, Nathan P, Wang D, Manyonda IT. Capillary remodeling in infants born to hypertensive pregnancy: pilot study. Am J Hypertens. 2012;25:848–853.
6. Taglauer ES, Fernandez-Gonzalez A, Willis GR, et al. Antenatal mesenchymal stem cell extracellular vesicle therapy prevents preeclamptic lung injury in mice. Am J Respir Cell Mol Biol. 2022;66:86–95.
7. Thébaud B. Preempting bronchopulmonary dysplasia: time to focus on the placenta? Am J Respir Cell Mol Biol. 2022;66:8–9.
8. Jakkula M, Le Cras TD, Gebb S, et al. Inhibition of angiogenesis decreases alveolarization in the developing rat lung. Am J Physiol Lung Cell Mol Physiol. 2000;279:L600–L607.
9. Le Cras TD, Markham NE, Tuder RM, Voelkel NF, Abman SH. Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure. Am J Physiol Lung Cell Mol Physiol. 2002;283:L555–L562.
10. Tang J-R, Karumanchi SA, Seedorf G, Markham N, Abman SH. Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol. 2012;302:L36–L46.
11. Yang WC, Chen CY, Chou HC, Hsieh WS, Tsao PN. Angiogenic factors in cord blood of preterm infants predicts subsequently developing bronchopulmonary dysplasia. Pediatr Neonatol. 2015;56:382–385.
12. Mirzakhani H, Carey VJ, McElrath TF, et al. Impact of preeclampsia on the relationship between maternal asthma and offspring asthma. An observation from the VDAART clinical trial. Am J Respir Crit Care Med. 2019;199:32–42.
13. Stokholm J, Sevelsted A, Anderson UD, Bisgaard H. Preeclampsia associates with asthma, allergy, and eczema in childhood. Am J Respir Crit Care Med. 2017;195:614–621.
14. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on hypertension in pregnancy. Obstet Gynecol. 2013;122:1122–1131.
15. Castillo A, Llapur CJ, Martinez T, et al. Measurement of single breath-hold carbon monoxide diffusing capacity in healthy infants and toddlers. Pediatr Pulmonol. 2006;41:544–550.
16. Feher A, Castile R, Kisling J, et al. Flow limitation in normal infants: a new method for forced expiratory maneuvers from raised lung volumes. J Appl Physiol. 1996;80:2019–2025.
17. ATS/ERS statement: raised volume forced expirations in infants: guidelines for current practice. Am J Respir Crit Care Med. 2005;172:1463–1471.
18. Gestational hypertension and preeclampsia: ACOG practice bulletin, number 222. Obstet Gynecol. 2020;135:e237–e260.
19. Davis SD, Ratjen F, Brumback LC, et al. Infant lung function tests as endpoints in the ISIS multicenter clinical trial in cystic fibrosis. J Cyst Fibros. 2016;15:386–391.
20. Davis SD, Rosenfeld M, Kerby GS, et al. Multicenter evaluation of infant lung function tests as cystic fibrosis clinical trial endpoints. Am J Respir Crit Care Med. 2010;182:1387–1397.
21. Nguyet TTD, Hoo A-F, Lum S, Wade A, Thia LP, Stocks J. New reference equations to improve interpretation of infant lung function. Pediatr Pulmonol. 2013;48:370–380.
22. Vojnow AJ, Feng R, Ren CL, et al. Pulmonary function tests in extremely low gestational age infants at one year of age. Pediatr Pulmonol. 2021;57:435–447.
23. Sengupta P. The laboratory rat: relating its age with human’s. Int J Prev Med. 2013;4:624–630.
24. Doyle LW, Ranganathan S, Haikerwal A, Cheong JLY, Victorian Infant Collaborative Study Group. Associations of preeclampsia with expiratory airflows in school-age children born either at <28 weeks or weighing <1000 g. J Pediatr. 2019;209:39–43.e2.
25. Nixon PA, Washburn LK, O’Shea TM. Antenatal steroid exposure and pulmonary outcomes in adolescents born with very low birth weight. J Perinatol. 2013;33:806–810.
26. Pole JD, Mustard CA, To T, Beyene J, Allen AC. Antenatal steroid therapy for fetal lung maturation: is there an association with childhood asthma? J Asthma. 2009;46:47–52.
27. Antonson AM, Evans MV, Galley JD, et al. Unique maternal immune and functional microbial profiles during prenatal stress. Sci Rep. 2020;10:20288.
28. Wright RJ. Perinatal stress and early life programming of lung structure and function. Biol Psychol. 2010;84:46–56.
29. Martinez FD, Morgan WJ, Wright AL, Holberg CJ, Taussig LM. Diminished lung function as a predisposing factor for wheezing respiratory illness in infants. N Engl J Med. 1988;319:1112–1117.
30. Turner SW, Palmer LJ, Rye PJ, et al. The relationship between infant airway function, childhood airway responsiveness, and asthma. Am J Respir Crit Care Med. 2004;169:921–927.
31. Yao W, Barbe-Tuana FM, Llapur CJ, et al. Evaluation of airway reactivity and immune characteristics as risk factors for wheezing early in life. J Allergy Clin Immunol. 2010;126:483–488.e1.
32. Balinotti JE, Chakr VC, Tiller C, et al. Growth of lung parenchyma in infants and toddlers with chronic lung disease of infancy. *Am J Respir Crit Care Med*. 2010;181:1093-1097.

33. Fitzgerald NM, Kennedy B, Fitzgerald DA, Selvadurai H. Diffusion capacity of carbon monoxide (DLCO) pre- and post-exercise in children in health and disease. *Pediatr Pulmonol*. 2014;49:782-789.

**How to cite this article:** Ren CL, Slaven JE, Haas DM, et al. Forced expiratory flows and diffusion capacity in infants born from mothers with pre-eclampsia. *Pediatric Pulmonology*. 2022;57:2481-2490. doi:10.1002/ppul.26064